INTRODUCTION
Metformin has been used in the treatment of type 2 diabetes for over 2 decades and, despite the development of newer agents, is the initial option for monotherapy recommended in guidelines in the US, Asia and Europe, including those of the American Diabetes Association and the International Diabetes Federation [1] . Metformin is regarded as a weight neutral agent in contrast to other oral hypoglycaemic agents and is the most commonly used biguanide, with a mode of action of reducing glucose production, enhancing the sensitivity of hepatic tissue to insulin and improving glucose muscle uptake [2] .
Changes in some glucose and lipid parameters have been very commonly reported in patients with all forms of severe mental illness (schizophrenia and bipolar disorder). It has been suggested that such changes may relate to a combination of genetic predisposition, lifestyle factors and psychotropic treatments. [3] [4] [5] [6] [7] . Changes in weight and metabolic parameters during treatment with atypical antipsychotics are among the risks that physicians consider in making treatment decisions for individual patients [5, 8, and 9 ].
An independent National Institute of Mental Health study in the US, CATIE, found clinically significant weight gain over 18 months to be very common, ranging from 30% in subjects taking olanzapine to 16% in those taking quetiapine, 14% in those taking risperidone, 12% in those on perphenazine and 7% in those on ziprasidone [4] . In another 6-month study among chronic schizophrenia subjects with predominantly negative symptoms, clinically significant weight gain was measured in 19% and 13% of the olanzapine-and quetiapine-treated cohorts, respectively [6] . In a 26 week study clinically significant weight gain >7% was measured in 40% of Olanzapine and 21% aripiprazole patients (p<0.05 between treatments).
[10].
The aforementioned studies were conducted predominantly in subjects with chronic schizophrenia. Data from first-episode treatment naïve and early psychosis, however, showed greater changes in weight and metabolic parameters [8, 9, and 12 ]. The EUFEST study, an independent European study of first-episode psychosis (FEP), found that 17% of subjects were already overweight according to their body mass index (BMI >25) and had significant metabolic dysfunction at baseline (hyperglycaemia 7%, 
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Deleted: Olanzapine was also associated with greater dyslipidaemia than the other agents in CATIE [4] . hyperlipidaemia 23%) [12] . During the 1-year study among subjects receiving antipsychotic treatment, 37-86% gained >7% body weight (p=.053 between treatments); 44% were overweight (p=0.585 between treatments); 28-56% had hypercholesterolemia (p=0.276 between treatments); and 22-30% had hyperglycaemia (p=0.794 between treatments). A prospective, randomised, Spanish FEP study utilising olanzapine, risperidone and haloperidol reported mean weight gain ranging from 8.9-10.9 kg at 1 year (treatment differences non significant), which equates to 75-87.% of each cohort gaining >7% body weight [8] .. Molindone, a first generation antipsychotic, has recently become utilised to treat children and adolescents with early onset schizophrenia spectrum disorders [11, 22] in whom weight and body image may be of significant concern. The 8-week TEOSS study reported significantly less weight gain in the molindone cohort than the olanzapine and risperidone cohorts [11] . A cochrane review in 2007 reported significantly more weight loss with molindone than other typicals (RR 2.78; CI 1.10-6.99; NNH 5 , CI 2-77).
[22] and the weight reduction potential of Molindone has been recognised since 1977 [63] There has been some degree of attention paid to prevention and/or reduction of weight gain over the last decade in subjects with severe mental illness, and there is general agreement that lifestyle interventions (LI) should precede any pharmacological treatments [3, [13] [14] [15] [16] . Even moderate weight loss of 5-15% of bodyweight may have significant health benefits [17] . Various types of LIs, ranging from a one-to-one nursing programme and behavioural groups to a telephone/postal service, have been undertaken [15, [18] [19] [20] . Many of these programmes have given encouraging results, but the results cannot be considered definitive as the controlled studies have tended to be short (12-14 weeks) and the uncontrolled studies and service evaluations, although showing positive results, often have tended to fail to retain subjects over the longer term [14, 15, 21] .In addition, there is only a single preliminary report of the usage of dietary/lifestyle management in an acute inpatient cohort despite literature suggesting rates of weight gain are typically greatest in early phases of treatment [20] .
A Cochrane review of behavioural programmes in schizophrenia found a body weight change in prevention studies of -4.87 kg at up to 24 weeks (confidence interval
[CI] -7.1, -2.6), but the weight change in reversal studies was only -1.69 kg (CI -2.8,-0.6)
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Deleted: Metabolic adverse effects may be measured in the absence of weight change [5] Deleted: and in first-episode subjects F o r P e e r R e v i e w O n l y PAGE 3 [14] . Various types of pharmacotherapy have also been tried, but the Cochrane review concluded these showed only a modest short-term benefit. Drugs studied in this Cochrane review include amantadine, dexfenfluramine, famotidine, fluoxetine, fluvoxamine, metformin, nizatidine, phenylpropanolamine, reboxetine, sibutramine and topiramate, with a reduction of 1.16 kg vs. controls in prevention studies increasing to a 3.85 kg reduction in reversal studies (p<0.05) [14] .
Metformin has been used in non-diabetic non-psychiatric populations with the aim of weight reduction and prevention of type 2 diabetes in high-risk cohorts and has shown some success. With regard to weight reduction, however, much of the data has been derived from uncontrolled studies and is not definitive [23, 24] . In the Diabetes Prevention Programme study, 3234 non-diabetic subjects with impaired glucose tolerance were randomised to metformin, LI or placebo arms over 4 years [25] . The incidence of diabetes mellitus (DM) was reduced by 58% in the LI arm and 31% in the metformin arm, with average weight loss of 5.6 kg and 2.1 kg, respectively, at the end of the 4-year period. Metformin has also shown success in weight reduction in females with polycystic ovary syndrome (PCOS We undertook a systematic review to identify all available clinical studies of subjects with schizophrenia, psychosis or bipolar disorder, in whom metformin has been investigated with the aim of either reducing weight gain or improving metabolic parameters.
METHODS

Data sources and study selection
We conducted an online literature search of the Biosis Previews (1989 to date), Current A total of 35 potential manuscripts were identified. After an initial review of these data, it was determined to include all study types regardless of methodology, thus not limiting the review to only randomised and blinded studies.
After viewing, 11 published studies were included.
Data extraction
Tables were created to record data from identified publications along with study methodology, sample and comparison populations and study period.
Statistical analysis
Statistical calculations from the source data are reported and no additional statistical analysis was performed.
RESULTS
Studies included
Eleven studies were identified and included a total of 495 subjects receiving antipsychotic medications (2 paediatric subjects received valproate only). Details of the 11 studies are presented in Tables 1 -4 .
Three of the studies involved paediatric and adolescent subjects with varying forms of psychosis [27, 29, 31] . Interpretation of one of the paediatric studies, the Arman et al. study, is complicated by the fact that a schizophrenia diagnosis was made in children (cohort mean ages 9-11 years). The remaining eight studies were all undertaken in adult schizophrenia subjects.
Five of the studies were conducted in Venezuela by the same investigator and it is not possible to evaluate any possible cohort overlap. The paediatric studies were undertaken in the US and Iran, and the remaining three studies in China and Taiwan.
Baseline weights and BMI reflected the predominant ethnicity of subjects (Asian and Hispanic). No adult study was undertaken in a Caucasian population.
Data synthesis
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Deleted: In five of the studies, all subjects received olanzapine, and seven of the studies contained a placebo cohort arm [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . In one of the paediatric studies, risperidone was administered to all subjects [31] . 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  O  n  l  y PAGE 3 The studies can be considered in two groups relating to cohort size. The five largest studies randomised 40 to 128 subjects in a double-blind manner. In the other six studies, between 5 and 38 subjects were included, and two of these studies were open label [27, 32] . Positive results were found in four of the five largest studies [30, 33, 34, 40] , with unequivocal positive results reported in the two most recent studies from China in first-episode subjects [30, 34] . Ten of the studies can be regarded as giving positive findings for metformin in terms of weight, BMI and other metabolic parameters.
Lifestyle and dietary interventions were included for all study participants in eight studies, and in the largest study LI formed a specific arm of the trial [30] . Although effective and superior to placebo, LI was inferior to both metformin and the combination of metformin with LI. Metformin with LI was however more effective than metformin alone [30] .
The studies can also be divided into FEP and chronic psychosis (predominantly schizophrenia). Two studies were undertaken in FEP, one focused on prevention [34] and one on reversal of early weight gain [30] and are both positive studies for metformin..
Only two other studies can be considered as preventative studies [30, 35] , and one of these constitutes the only negative study of metformin on weight [35] .
Seven of the studies included a placebo cohort ,olanzapine was the only antipsychotic given in five out of 11 studies; one study used only risperidone [31] , one used only clozapine [40] and the other studies included small numbers of subjects on various antipsychotics with. Data synthesis did not allow any meta-analytic calculation due to a lack of homogeneity amongst study design and the confounding nature of the lifestyle interventions.
.
DISCUSSION
Overview
Our systematic review of the 11 studies of metformin in subjects with schizophrenia and psychosis found that there is no unequivocal answer as to the value of using routine adjunctive metformin. Many of the studies do, however, provide promising data to suggest that definitive work in this cohort of subjects prone to adverse metabolic outcomes might be valuable. In ten out of the 11 studies, the results of weight change in Can these data be regarded as definitive for guideline development?
There are significant limitations to any interpretation of this eclectic mix of studies that include an absence of Caucasian cohorts. Many of the studies do not give clear data on whether any powering was undertaken to establish cohort size. Almost all the subjects had a diagnosis of schizophrenia and most subjects were receiving olanzapine; hence, extrapolation to any other treatment populations or medications may be presumptive. In addition, all the studies were short term (8-16 weeks) , and this may be regarded as too short a time period over which to make any conclusions. Longer term studies are required to inform on any potential CVD risk reduction by metformin. The temporal course of weight gain and metabolic change has not been fully established in schizophrenia, although current data suggest that rates of weight gain are typically greatest in early phases of treatment and very common in FEP regardless of antipsychotic [8, 9, 22] . The CATIE Phase I cohort that was given olanzapine had initial cholesterol elevation that reverted to baseline measurements by 9 months into the study [37] . Additionally, the numbers of olanzapine subjects with abnormal glucose (>100 mg/dl) fell from 35% to 27% at 3 months [38] . Such data make it complex to suggest a specific time period for any future clinical research of metformin in metabolic regulation.
We found no data on metformin usage in other forms of severe mental illness such as bipolar disorder . .
Should metformin be utilised in conjunction with weight management and lifestyle programmes?
It is complex to try and separate any metformin effects from those of adjunctive weight, lifestyle and exercise programmes, as these were utilised in eight studies for all participants.. In the largest and best designed study (due to its randomised double blind design, larger patient numbers and testing of multiple interventions) , metformin alone was found to be superior to LI on weight and glucose measures, but the combination of metformin and LI was superior to metformin with regard to body weight and BMI reductions [30] . This contrasts with findings from a large study in non-diabetic nonmentally ill subjects at risk of diabetes in whom metformin did reduce both weight and DM incidence over 4 years but was inferior to LI. Data generated from the general population may not necessarily be extrapolated to the schizophrenia population [25] .
Such programs were relatively short in duration, but they were often effective, and may have masked positive effects of metformin. In addition, many subjects were chosen for the studies who were highly motivated to achieve weight loss or who had family situations that would encourage correct administration of the LI [30] . In the original case series, subjects whom were well motivated to lose weight lost 3.3 kg (+ -1.7) over the initial 4 weeks without metformin and subsequently lost 1.3 kg (+ -1.1) during 8 weeks of metformin treatment [28] . In a later cohort (n = 28) randomised to metformin/sibutramine or placebo, all subjects received a comprehensive programme regarding "healthy lifestyle" [36] . The study was not powered to show any differences but, despite the success of the lifestyle programme, weight loss was numerically greater in the metformin/sibutramine cohort than placebo (-2.8 kg vs. -1.4 kg; p = 0.19). Lipid and glucose parameters showed numerically greater improvement in the active cohort, which only reached significance with a greater triglyceride reduction (p = 0.012). Thus, the improvement being observed in weight, glucose and most lipid parameters in the placebo cohort can only be attributed to the lifestyle programme. In the largest study in chronic subjects (n = 80), predominantly with schizophrenia, where again some weight management programme was provided, significant weight loss was achieved in the metformin cohort over 12 weeks, 1. PAGE 3 was no difference compared to the placebo group, as weight was maintained in that cohort, presumably due to the weight management programme [33] .
In one of the three studies in which weight management was not provided, a chronic and severe schizophrenia inpatient cohort was provided with a calorie-"restricted" diet of 2500-3000 kcals [35] . This study found significant steady weight gain in both the metformin and placebo cohorts, with increases of 5.5 and 6.3 kg, respectively, over 14 weeks. Antipsychotic dosage was high as subjects continued with their depot schedule (fluphenazine decanoate 25 mg or haloperidol 100 mg monthly) in addition to commencing olanzapine 10 mg daily. The second Asian study evaluated placebo, metformin, metformin and lifestyle changes (LC), or LC alone over 12 weeks [30] . This is the largest of the studies and included 128 subjects with first-episode schizophrenia whom had gained >10% of their pre-drug weight. The LC plus metformin cohort had the largest decrease in BMI of 1.8 (95% CI 1.3-2.3) with significant improvement in insulin resistance, followed by metformin and then LC alone, with all three groups reporting decreases in BMI and insulin resistance. In contrast, in the placebo cohort there was an increase in BMI and worsening of insulin resistance. Importantly, this study concluded that the combination of metformin and LC was the most effective regimen, and individually metformin was Deleted: The study population included clinically stable but severe schizophrenia inpatients whom might be considered less likely candidates for good response to a weight management programme.
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Deleted: In the EUFEST study, the olanzapine cohort had a mean weight gain of 13.9 kg (standard error (SE) 1.7) after a year with no weight management intervention [12] . Programme from the UK in addressing all these valid cardiovascular disease (CVD) risk factors [3, 19] . A further strength of this study was that subjects were receiving a variety of antispsychotics (clozapine, olanzapine, risperidone and sulpiride), and hence conclusions are not restricted to olanzapine subjects only.
Do adverse events during treatment with metformin preclude usage in SMI?
The most common adverse event associated with metformin was mild gastrointestinal discomfort and with no unexpected adverse events and high completion rates the studies, In. Despite some speculation that metformin may reduce IGF-1, and hence worsen symptomatology, there seems to be no evidence in this systematic review to support any deterioration of the mental state [47, 48] .
What is known about metabolic and coagulant parameters in these studies?
Lipids
Changes in lipids were only measured in five studies. There were no consistent changes in lipids, although confounding by the potential benefit of a lifestyle programme and the short term nature of the studies makes interpretation complex. The metformin/sibutramine and the clozapine studies report beneficial changes in most lipid parameters [36, 40] .. In a larger study over 12 weeks there were no differences between metformin and placebo with a trend for superiority in the placebo cohort [33] . In a chronic inpatient cohort on metformin without weight management, lipid changes tended Deleted: Subjects had been on treatment for 8 months and, importantly, can also be regarded as in an early phase of their illness. In due course CVD outcomes will be needed to assess any longer term benefits of metformin [41-45, 49, 50] ¶ Deleted: In one inpatient study over 12 weeks, there was an increase in the Brief Psychiatric Rating Scale (BPRS) in both active (+20.7 +/-12.2) and placebo (+14.7 +/-9.4) cohorts that was ascribed to the stress of the lifestyle programme [36] . In an earlier case series, the same author, working with motivated outpatients, reported a reduction in BPRS (p = 0.039) during the initial placebo phase that did not change during the subsequent metformin phase [28] where no lifestyle programme was given. In chronic inpatients who began on olanzapine in addition to a depot typical, BPRS significantly improved in both the metformin and placebo cohorts, mainly over an initial 7-week period [35] . Clinical Global Impressions and Global Assessment of Functioning scores remained stable over 8 weeks with metformin [32] . ¶ Additionally, in first-episode subjects in a placebo-controlled 12-week study, there were no clinical effects on either the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms [34] . Among Deleted: first-episode subjects treated for 8 months in the largest metformin study, there were also no increases in any adverse events in the metformin cohorts compared with placebo [30]. Positive and Negative Syndrome Scale scores did not alter from baseline in any of the metformin or other cohorts Deleted: Elevation in triglycerides were significantly reduced in the metformin/sibutramine treatment group (p = 0.012) but not in the placebo group to be significantly better in the metformin cohort despite significant weight gain in both cohorts over 14 weeks [35] . Finally, in a Taiwan-based cohort of 24 subjects studied over 8 weeks, triglyceride was the only lipid to decrease significantly [32] .
Glucose
Changes in glucose were reported in nine studies. Interpretation of glucose changes is complex due to the confounders of weight management and altered diets; however, in general terms metformin was associated with beneficial changes. The original small case series found that whilst glucose and insulin parameters improved during the placebo phase, there was significant worsening during the metformin phase in both glucose and insulin area under the curve [28] . However, most data are consistent with the known profile of metformin. In the 12-week placebo study of subjects with chronic schizophrenia and the clozapine study, glucose remained unaltered in both cohorts, but beneficial changes in HOMA-IR and insulin were found in metformin cohorts [33, 40] . In a further study in chronic schizophrenia inpatients, patients treated with metformin These treatments, given together or individually, were also all superior to placebo in cases where increases in these parameters were measured. These reductions were measured at 4 weeks for the metformin cohorts. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 PAGE 3 Three of these studies have evaluated changes in markers of endothelial dysfunction (CRP), procoagulant states ( fibrinogen) and leptin associated with metformin and have reported preliminary data [33, 36, 40] . The data potentially suggest that metformin may decrease leptin however no statistically significant changes have been reported. In a 12-week placebo controlled study metformin was associated with a tendency to decrease leptin (p=0.078), with leptin and body weight correlating positively, but with no changes in other parameters (CRP, fibrinogen, cortisol and growth hormone) [33] . Further posthoc analysis suggested that CRP levels reduced in women (p=0.016) but not men in the metformin cohort however a similar trend was found in the placebo cohort. In the second 12-week study metformin in combination with sibutramine was not associated with any difference from placebo in leptin or fibrinogen [36] although there was a reduction in fibrinogen from baseline in the metformin/sibutramine cohort. No conclusions can be drawn from these data however larger and longer studies may be indicated, as these factors may be critical in the development of cardiovascular disease. In a more specific study over 14-weeks leptin decreased non-significantly in the metformin cohort contrasting with a small increase in the placebo cohort [62] . Fibrinogen decreased in both cohorts whereas CRP was unchanged.
Metformin for weight reduction in the general population. Are there differences compared with SMI subjects?
Metformin is regarded as weight neutral when used as an antihyperglycaemic agent in type 2 diabetic subjects. This is in contrast to sulphonylureas, glitazones and insulin [2] .
The value of metformin in overweight subjects with type 2 diabetes as a cardioprotective and mortality reducing agent has been established by an all-cause mortality reduction of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 A meta-analysis and systematic review from the Cochrane group that analyzed metformin usage in PCOS concluded that although there were reports of weight loss during treatment, this was not found to be significant on meta-analysis [55] . Of note, many of the studies in the meta-analysis had small cohorts and were of short duration.
Open and randomised studies have continued to postulate that metformin when used for PCOS may be a successful weight reduction agent, although the degree of weight loss may not be great [56, 57] . In a cohort of women with PCOS whom were obese (BMI >30) and morbidly obese (BMI >37), doses of metformin 1500-2550 mg/day over 8 months along with "advice on diet and exercise" resulted in a weight loss of only 1.5-3.6 kg in the obese cohort (p = 0.04) and 3.8-3.9 kg in the morbidly obese cohorts [56] .
Metformin has also been combined with fluoxetine in an open-label pilot study in females performed in an obesity clinic with the active cohort achieving BMI reduction of 3.43 over 6 months [58] . The usage of metformin in child and adolescent obesity has also been debated, with a cautious conclusion that in short-term small trials metformin may have some benefit in weight reduction [59] . The most recent review of metformin and its effects on weight in a general population excluded studies evaluating PCOS and the Deleted: This study speculated that higher metformin doses may be required. conclusions are similar to those mentioned above [24] . The five trials where weight was a primary outcome are small (26-66 metformin subjects), of short duration (3-7 months) and none are randomised or placebo controlled. As with our review, many of these studies also include weight and LI programmes as well as motivated subjects. The precise benefits of metformin are, therefore, difficult to determine precisely. In the seven studies where weight was a secondary outcome, the duration of the studies tended to be longer, but weight reduction was less in the shorter-term studies. Also, in the randomised placebo-controlled studies, weight loss on metformin was only slightly better than on placebo (1.2-2.5 kg) in trials lasting more than 12 months. In the six adolescent trials, the results again showed modest weight loss and had similar flaws to the adult trials. The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Study NCT 00816907 is a pilot study (n=80) in adult schizophrenia or schizoaffective subjects with BMI >27 kg/m2 over 16 weeks measuring various metabolic parameters due to complete august 2009 and which allows a larger definitive trial to be designed.
Study NCT 00617240 is a placebo controlled 24-week randomised study in subjects 10-17 years receiving antipsychotics also measuring metabolic parameters due to complete January 2010. In both these studies all subjects will receive a form of lifestyle intervention.
CONCLUSION
Despite some promising data, there seems to be insufficient current evidence to conclude definitively that metformin should be used as an adjunct to weight and lifestyle programmes in patients with schizophrenia. All the current data is essentially short term, mostly 12-week studies, and any conclusions can only be applied to olanzapine and the ethnic cohorts investigated. No Caucasian subjects have been studied. The most promising data are in subjects with FEP where metformin is used as either a prophylactic agent or to reduce early weight and metabolic changes. These limited studies suggest that metformin seems to have few specific adverse events when utilised in this way. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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psychotropic drugs but those know to effect body weight must have been at on a stable regime for at least 30 days prior to study and remain on that regime during the course of the study. MET 850mg/day (n=11), RIS (n=14)or QUET (n=14).
Diagnoses were
recommended at the end of the study for children with BMI>95 th percentile for their age or gain of >10% of baseline weight during the study associated with high FI (>20uU/ml) or FG (>95mg/dL).
weight and body mass index (z scores) were determined Z scores for BW and BMI decreased in the MET group and increased in the PBO group (p values not stated) (Between Group) Differences were significant at all time points for BW & BMI (week 16 p<.0001) and at weeks 8, 12, & 16 for WC (week 16 p=.003) Z scores were significantly lower in the MET group than PBO group for BW ((p=.0008) and BMI (p=.0006) at week 16.
Glucose Related (Within Group)
HOMA-IR increased in the AAP+PBO group and decreased in the AAP +MET group. (p values not stated) (Between Group) The differences in HOMA-IR were marginally significant at weeks 4 (p=.08) and significant at week 8 (p=.03) but not at week 12 (p=.17) Significantly fewer children in the AAP +MET group than the AAP + PBO group were recommended for OGTT. (2 vs 10 respectively p<.01) 
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Systematic review of metformin in non-diabetic SMI subjects (Bushe, Bradley, Doshi and Karagianis 2008) PAGE 3 Weight Related (within group) A significant decrease in BW was seen in the CLZ+MET group at weeks 7 (p=0.01) and week 14 (p=0.01). A significant decrease in BMI was seen in the CLZ +MET group at weeks 7 (p=0.01) and week 14 (p=0.01). A significant derease in WC was seen in the CLZ +MET group at week 7 (p=0.04) Between Group CLZ + MET was significantly superior to CLZ + PBO on BW (p=0.01) and BMI (p=0.01) at week 14.
Glucose related (Within group)
There was a significant decrease in SG at week 7 in the CLZ+MET group (p=0.01) and CLZ+PBO group (p=0.05) There was a significant decrease in SI in the CLZ+MET group at week 14 (p=0.004) There was a significant increase in HbA1c at week 14 in the CLZ+MET group (p=0.006) and the CLZ+PBO group (p=0.001). HOMA-IR decreased siginficatly in the CLZ+MET group at week 14 (p=0.02).
(Between group)
There was a significantly greater reduction in SI at week 14 in the CLZ+MET group than the CLZ+PBO group (p=0.04) The increase in HbA1c at weeks 7 (p=0.03) and week 14 (p=0.04) was significantly greater in the CLZ+PBO group than the CLZ+MET group.
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Systematic review of metformin in non-diabetic SMI subjects (Bushe, Bradley, Doshi and Karagianis 2008)
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Lipid Related (Within group) HDL-C increased significantly in the CLZ+MET group at week 7 (p=0.001) and week 14 (p=0.01) TG:HDL-C ratio decreased significantly in the CLZ+MET group at week 14 (p=0.04) (Between group) HDL-C increased significantly more in the CLZ+MET group than the CLZ +PBO group at week 7 (p=0.002) and week 14 (p=0.001). TG:HDL-C ratio decreased significantly in the CLZ+MET vs. the CLZ+PBO group at week 14 (p=0.02) Wu et al (2008) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 O n l y To compare the safety and effectiveness of OLZ, PER and ARI, with additional medications, MET, simvastain and benztropine to limit treatment side effects, in adults with schizophrenia.
Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study Patients randomised under single blind (outcomes assessor) conditions to OLZ, ARI or PER. Side effects to all three antipsychotics monitored, and, depending on the side effect medications added to the treatment regimen. Increased cholesterol simvastatin added; weight gain, MET added; EPS benztropine added. Participants assigned to olanzapine or perphenazine automatically add MET or benztropine, respectively, to their regimens. Participants will also undergo a behavioural treatment aimed at reducing cardiovascular risk factors.
Outcome of antipsychotic efficacy is defined as completion of the trial without psychiatric hospitalization, clinician decision to discontinue treatment, or patient decision to discontinue treatment. Other outcomes -vital signs, WC, BW. To assess the efficacy of switching from OLZ, QUET or RISP to ARI compared to the addition of MET to current antipsychotic therapy or continuation of current antipsychotic alone.
Treatment, Randomized, Single Blind (Outcomes Assessor), Factorial Assignment, Safety/Efficacy Study. 24 weeks. Participants randomly assigned to one of three conditions:
1. gradual switch of current AAP medication to ARI, 2. addition of metformin to current AAP medication, To evaluate the effectiveness, safety, and tolerability of MET treatment in children and adolescents suffering from weight gain secondary to use of OLZ, QUET or RISP.
Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study.12 weeks. Patients will continue on their current antipsychotic and have MET added. At consent patients were given healthy lifestyle advise but patients were asked NOT to change lifestyle or diet during the study. To determine whether starting MET in conjunction with an AAP and LSI will prevent or reduce the amount of weight gain and the metabolic changes in adolescent youth typically seen with AAP medication.
